Advances in Inflammatory Bowel Diseases 2018 - Clinical Track

Advances in Inflammatory Bowel Diseases 2018 - Clinical Track

On-Demand Webcast
Conference Chairs

Richard P. MacDermott, MD, MACG
Emeritus Professor of Medicine
Albany Medical Center
Albany, New York

Stephen B. Hanauer, MD, FACG
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Miguel D. Regueiro, MD, FACG
Cleveland Clinic
Cleveland, Ohio

Faculty

Faten N. Aberra, MD, MSCE
University of Pennsylvania
Philadelphia, Pennsylvania

Maria T. Abreu, MD
University of Miami Miller School of Medicine
Miami, Florida

Anita Afzali, MD, MPH, FACG
Ohio State University
Wexner Medical Center
Columbus, Ohio

Jessica R. Allegretti, MD, MPH
Brigham and Women’s Hospital
Harvard University
Boston, Massachusetts

Ashwin N. Ananthakrishnan, MD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Monica I. Ardura, DO, MSCS
Nationwide Children’s Hospital
Columbus, Ohio

Jean H. Ashburn, MD
Wake Forest University
Baptist Medical Center
Winston-Salem, North Carolina

Robert N. Baldassano, MD
Children’s Hospital of Philadelphia
University of Pennsylvania
Philadelphia, Pennsylvania

Willem A. Bemelman, MD, PhD
Amsterdam University Centers
Amsterdam, Netherlands

Charles Bernstein, MD
University of Manitoba
Winnipeg, Canada

Meenaskshi Bewtra, MD, PhD, MPH
University of Pennsylvania
Philadelphia, Pennsylvania

David Binion, MD, FACG
University of Pittsburgh
Pittsburgh, Pennsylvania

Eugene B. Chang, MD
University of Chicago Medicine
Chicago, Illinois

Adam S. Cheifetz, MD, FACG
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Jean-Frederic Colombel, MD
Icahn School of Medicine at Mount Sinai
New York, New York

Raymond K. Cross, Jr., MD, MS
University of Maryland Medical Center
University of Maryland School of Medicine
Baltimore, Maryland

Amy M. Donegan, APRN
Nationwide Children’s Hospital
Columbus, Ohio

Marla Dubinsky, MD
Mount Sinai Hospital Icahn School of Medicine
New York, New York

Francis A. Farraye, MD, MSc, FACG
Boston Medical Center
Boston University School of Medicine
Boston, Massachusetts

Brian G. Feagan, MD, FACG
London Health Sciences Centre
Western University
London, Canada

Alessandro Fichera, MD
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Phillip Fleshner, MD
Cedars-Sinai Medical Center
Los Angeles, California

Sonia Friedman, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Jill K.J. Gaidos, MD, FACG
McGuire VA Medical Center
Virginia Commonwealth University
Richmond, Virginia

Jesse A. Green, MD
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Anne M. Griffiths, MD
The Hospital for Sick Children
University of Toronto
Toronto, Canada

Andrew B. Grossman, MD
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Christina Y. Ha, MD
Cedars-Sinai Medical Center
Los Angeles, California

Stephen B. Hanauer, MD, FACG
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Rachel Hendee, PA-C, MPH
Rush University Medical Center
Chicago, Illinois

Stefan Holubar, MD
Cleveland Clinic Foundation
Cleveland, Ohio

Sara N. Horst, MD, MPH
Vanderbilt University Medical Center
Vanderbilt University
Nashville, Tennessee

David P. Hudesman, MD
NYU Inflammatory Bowel Disease Center
New York, New York

Caroline Hwang, MD
University of Southern California
Los Angeles, California

Neil H. Hyman, MD
University of Chicago Medicine
Chicago, Illinois

Kim L. Isaacs, MD, PhD, FACG
UNC Hospitals
University of North Carolina
Chapel Hill, North Carolina

Sunanda V. Kane, MD, MSPH, FACG
Mayo Clinic
Rochester, Minnesota

Laurie A. Keefer, PhD
Icahn School of Medicine at Mount Sinai
New York, New York

Maureen Kelly, DNP
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Sergey Khaitov, MD
Icahn School of Medicine at Mount Sinai
New York, New York

Sandra C. Kim, MD
University of Pittsburgh
Pittsburgh, Pennsylvania

Donald Kirby, MD
Cleveland Clinic Foundation
Cleveland, Ohio

Walter A. Koltun, MD
Penn State Health
Hershey, Pennsylvania

Asher Kornbluth, MD
Icahn School of Medicine at Mount Sinai
New York, New York

Paulo G. Kotze, MD, MSc
Catholic University of Paraná
Curitaba, Brazil

L. Campbell Levy, MD
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Gary R. Lichtenstein, MD, FACG
University of Pennsylvania
Philadelphia, Pennsylvania

Amy L. Lightner, MD
Mayo Clinic
Rochester, Minnesota

James Lindsay, MD
Barts Health NHS Trust
London, United Kingdom

Edward V. Loftus, Jr., MD, FACG
Mayo Clinic
Rochester, Minnesota

Millie D. Long, MD, MPH, FACG
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Nicole Lopez, MD
University of California, San Diego
San Diego, California

Richard P. MacDermott, MD, MACG
Emeritus Professor of Medicine
Albany Medical Center
Albany, New York

Kristen Madden, ARPN-PNP
Children’s Hospital and Medical Center
Omaha, Nebraska

Alan C. Moss, MD, FACG
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Mark T. Osterman, MD, MSCE
University of Pennsylvania
Philadelphia, Pennsylvania

Miguel D. Regueiro, MD, FACG
Cleveland Clinic
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Feza Remzi, MD
NYU Langone Medical Center
New York, New York

David T. Rubin, MD, FACG
University of Chicago Medicine
Chicago, Illinois

Michele Rubin, APN, MSN, CNS, CGRN
University of Chicago Medicine
Chicago, Illinois

William J. Sandborn, MD, FACG
University of California, San Diego
San Diego, California

Bruce E. Sands, MD, MS, FACG
Icahn School of Medicine at Mount Sinai
New York, New York

David A. Schwartz, MD, FACG
Vanderbilt University
Brentwood, Tennessee

Bo Shen, MD
Cleveland Clinic Foundation
Cleveland, Ohio

Corey A. Siegel, MD, MS
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Daniela Simian, RN
Clinica Las Condes
Santiago, Chile

Scott Strong, MD
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Eva M. Szigethy, MD, PhD, FACG
University of Pittsburgh Medical Center
University of Pittsburgh
Pittsburgh, Pennsylvania

Lauren K. Tormey, MD
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Thomas A. Ullman, MD, FACG
Albert Einstein College of Medicine
Bronx, New York

Daniel von Allmen, MD
Cincinnati Children’s Hospital Medical Center
University of Cinncinnati
Cincinnati, Ohio

Douglas C. Wolf, MD, FACG
Atlanta Gastroenterology Associates
Atlanta, Georgia

Karen Zaghiyan, MD, FACS
Cedars Sinai Medical Center
Los Angeles, California

Target Audience

This educational activity is designed for gastroenterologists and other healthcare professionals (physicians-in-training, nurses, pharmacists, physician assistants, etc) involved and/or interested in the therapeutic management of patients with IBD.

Overview

The therapeutic landscape of IBD has evolved significantly over recent years, and new medication approvals, biosimilar approvals, and other potential targeted therapies for IBD are emerging at a rapid pace. These novel therapies have led to significant improvements in the clinical management of IBD and have led to recommendations for earlier diagnosis and personalized treatment. With these rapid advances, clinicians are challenged to critically assess emerging data and to implement safe and effective solutions for current clinical challenges. Clinicians need expert guidance to help them integrate new and promising data into their clinical practices.

Designed to meet the educational needs of the entire IBD healthcare team, the 2018 Advances in Inflammatory Bowel Diseases (AIBD) meeting provided clinicians with expert guidance on the latest advances and new insights for the personalized care of patients with IBD. This webcast highlights the clinically significant information presented during the 2018 AIBD ‘Clinical Track’ in Orlando, Florida on December 13-15, 2018.

Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Offer rationales for the positioning of therapies in emerging drug classes, including lymphocyte trafficking inhibitors, IL-12/23 inhibitors, and JAK inhibitors
  2. Summarize ACG guidelines for the treatment of severe Crohn’s disease and ulcerative colitis
  3. Employ strategies to optimally manage opportunistic infections in IBD, including clostridium difficile and other bacteria, viruses, and fungal complications
  4. Describe considerations for de-escalating, restarting, and switching biologic therapies
  5. Discuss issues of interest with women with IBD who are of childbearing age, such as sexual dysfunction, infertility, and continuing IBD therapy while pregnant
  6. Outline strategies for the prevention of post-operative recurrence of Crohn’s disease
  7. Describe management considerations for complex IBD cases involving malignancy

Release Date: December 21, 2018

Expiration Date: December 21, 2019

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Support

Supported by educational grants from AbbVie, Inc., Celgene Corporation, Gilead Sciences, Inc., Pfizer, and Takeda Pharmaceuticals U.S.A., Inc.

Accreditation

Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.

 


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

PHYSICIANS

Imedex designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 11.50 AAPA Category 1 credits.

PAs should only claim credit commensurate with the extent of their participation.

CNE

This continuing nursing education activity awards 11.50 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 11.50 contact hours.

CPE

This knowledge-based activity (JA0006201-9999-18-249-H01-P/JA0006201-9999-19-122-H01-P) is approved for 11.50 contact hours (1.15 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Stephen B. Hanauer, MD, FACG, Richard P. MacDermott, MD, MACG, MIguel D. Regueiro, MD, FACG; and Chris Bolwell, Monalisa Singh, and Susan Yarbrough, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

All faculty are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Faten N. Aberra, MD, MSCE AbbVie1; Celgene1; Janssen1,2; UCB1
Anita Afzali, MD, MPH, FACG AbbVie3; IBD Horizons3; Janssen3; Pfizer3; Takeda3; UCB3
Jessica R. Allegretti, MD, MPH AbbVie2; Janssen2; Merck2
Ashwin N. Ananthakrishnan, MD, MPH Merck2; Takeda2
Robert N. Baldassano, MD Celgene2; Janssen2; Lilly2; Pfizer2
Willem A. Bemelman, MD AbbVie3; Braun1; Janssen3; Johnson & Johnson3; Meddtronic1; Takeda3; Vifor1
Charles Bernstein, MD AbbVie Canada1,2; Ferring Canada3; Janssen Canada1,2; Medtronic3; Mylan Pharmaceuticals2; Pfizer Canada1,2; Shire Canada1,2; Takeda Canada2,3
Meenaskshi, Bewtra, MD, PhD, MPH Med Learning Group2; Takeda1; Vindico2
David G. Binion, MD, FACG AbbVie1,2; Janssen Biotech2; Merck1,2; Shire1; Takeda1
Adam S. Cheifetz, MD, FACG Miraca1,2
Jean-Frederic Colombel, MD AbbVie1,2,3; Amgen2; Boehringer Ingelheim2; Arena Pharmaceuticals2; Celgene Corporation2,3; Celltrion2; Enterome2; Eli Lilly2; Ferring Pharmaceuticals2,3; Genentech2; Genefit 4; Intestinal Biotech Development4; Janssen and Janssen1,2; Medimmune2; Merck & Co2; Nextbiotix2; Novartis Pharmceuticals Corporation2; Otsuka Pharmaceutical Development & Commercialization2; Pfizer2; Protagonist2; Gilead2; Seres Therapeutics2; Shire2; Takeda1,2,3; Theradiag2; Zealand Pharma2
Raymond K. Cross, Jr., MD, MS AbbVie1,2; Janssen2; Pfizer2
Marla Dubinsky, MD AbbVie1,2; Celgene2; Genentech2; Janssen1,2; Lilly2; Pfizer1,2; Prometheus2; Takeda2; UCB2
Francis A. Farraye, MD, MSc, FACG Braintreee2; Ferring2; Innovation2; Janssen2; Lilly2; Merck2; Pfizer2; Protagonist2; Takeda2
Brian G. Feagan, MD, FACG Abbott1,2,3; AbbVie1,2,3; Ablynx2; Akebia Therapeutics2; Allergan2; Amgen1,2; Applied Molecular Transport Inc.2; Aptevo Therapeutics2; AstraZeneca1,2; Atlantic Pharmaceuticals Ltd.1,2; Avaxia Biologics Inc.2; Avir Pharma2; Baxter Healthcare Corp.2; Biogen Idec2; Boehringer Ingelheim1,2; Bristol-Myers Squibb2; Calypso Biotech2; Celgene Corporation1,2; Celgene International1; Celltech1; Centocor Inc.2; Elan/Biogen2; EnGene2; Ferring Pharma2; Galapagos2; Genentech Inc.1,2; GiCare Pharma2; Gilead Sciences Inc.1,2; Given Imaging Inc.2; GlaxoSmithKline1,2; Hoffmann-La Roche Ltd.1; Inception IBD Inc.2; Ironwood Pharma2; Janssen2,3; Janssen Biotech2; Janssen Research & Development LLC.1; Johnson & Johnson2,3; Kyowa Kakko Krin Co Ltd.2; Lexicon2; Lilly2,3; Lycera BioTech2; Medimmune Ltd.1; Merck2; Mesoblast Pharma2; Millennium2; Nektar2; Nestle2; Nextbiotix2; Novartis2; Novonordisk2; Pfizer Inc.1,2; Prometheus Laboratories2; Prometheus Therapeutics and Diagnostics2; Progenity2; Protagonist2; Receptos Inc.1,2; Roche2; Salix Pharma2; Sanofi1; Santarus Inc.1; Serono2; Shire2; Sigmoid Pharma2; Sterna Biologicals2; Synergy Pharma Inc.2; Takeda2,3; Takeda Development Center Americas Inc.1; Teva Pharma2; TiGenix2; Tillotts Pharma AG1,2; UCB Pharma1,2,3; Vertex Pharma2; Vivelix Pharma2; VHsquared Ltd.2; Warner-Chilcott2; Wyeth2; Zealand2; Zyngenia2
Jill K.J. Gaidos, MD, FACG Celgene2; Takeda3
Jesse A. Green, MD Covidien5; Medtronics5
Anne M. Griffiths, MD AbbVie1; Gilead2; Merck2; Roche2; Shire3
Andrew B. Grossman, MD Abbott Pediatrics3
Christina Y. Ha, MD AbbVie2,3; Ferring2; Janssen2; Pfizer2; Takeda2
Stephen B. Hanauer, MD, FACG AbbVie1,2,3; Actavis2; Allergan1,2; Amgen1,2; Arena2, Boehringer Ingelheim2; Bristol-Myers Squibb2; Celgene1,2; Celltrion2; Ferring2; Genentech1,2; GlaxoSmithKline1,2; Hospira2; Janssen1,2,3; Lilly1,2; Merck2; Nestle2; Novartis1,2; Pfizer1,2; Prometheus1,2; Receptos1,2; Salix2; Samsung Bioepis2; Sanofi-Aventis1,2; Seres Health2; Shire2; Takeda1,2,3; Therakos2; Tigenex2; UCB Pharma1,2; VHsquared2
Sara N. Horst, MD, MPH Janssen2
David P. Hudesman, MD AbbVie2; Janssen2; Pfizer2; Takeda2
Caroline Hwang, MD AbbVie1; Janssen3; Nestle1; Pfizer3
Kim L. Isaacs, MD, PhD, FACG Allergan2; Janssen2; Medimmune2
Sunanda V. Kane, MD, MSPH, FACG AbbVie2; Samsung Bioepis2; Seres Therapeutics2; Spherix Health2
Laurie A. Keefer, PhD AbbVie1; metaME Connect4; Pfizer1,2
Walter A. Koltun, MD Biosciences2; Recro Pharma2
Asher Kornbluth, MD AbbVie2,3; Janssen2,3; Merck2,3; Pfizer2,3; Salix2; Takeda2,3
Paulo G. Kotze, MD, MsC, PhD AbbVie2,3; Janssen2,3; Pfizer2,3; Takeda2,3
Gary R. Lichtenstein, MD, FACG AbbVie2; American College of Gastroenterology5; Celgene1,2; CellCeutrix2; Clinical Advances in Gastroenterology5; Ferring2; Gastroenterology and Hepatology5; Gilead2; Janssen Orthobiotech1,2; Luitpold/American Regent2, Merck2; McMahon Publishing5; Pfizer Pharmaceuticals2; Prometheus Laboratories, Inc.2; Romark2; Salix Pharmaceuticals/Valeant1,2; Shire Pharmaceuticals1,2; SLACK, Inc5; Springer Science and Business Media5; Takeda2; UCB1,2; Up-To-Date5
Amy L. Lightner, MD Takeda2
James Lindsay, MD AbbVie3; Celtrion3; Falk3; Ferring3; Janssen3; Pfizer1,2; Shire2; Takeda2
Edward V. Loftus, Jr., MD, FACG AbbVie1,2; Allergan2; Amgen1,2; Bristol-Myers Squibb2; Celgene1,2; Celltrion2; Eli Lilly2; Genentech1; Gilead1; Janssen1,2; Medimmune1; Pfizer1,2; Robarts Clinical Trials1; Takeda1,2
Millie D. Long, MD, MPH, FACG AbbVie2,3; Janssen2; Pfizer1,2; Takeda1,2; Target Pharmasolutions2; UCB2,3
Alan C. Moss, MD, FACG Boehringer Ingelheim2; Janssen2; Seres Therapeutics2; Theravance2
Mark T. Osterman, MD, MSCE AbbVie2; Lycera2; Merck2; Pfizer2; Takeda2; UCB1
Miguel D. Regueiro, MD, FACG AbbVie2; Allergan2; Amgen2; Celgene2; Janssen2; Miraca Labs2; Pfizer2; Seres2; Takeda2; UCB2
David T. Rubin, MD, FACG AbbVie1,2; Abvenomics2; Allergan, Inc.2; American College of Gastroenterology5; Amgen2; Celgene Corporation2; Cornerstones Health, Inc.5; Forward Pharma2; Genentech1,2; GoDuRn, LLC5; Janssen Pharmaceuticals1,2; Merck & Co., Inc.2; Miraca Life Sciences2; Mitsubishi Tanabe Pharma Development America, Inc.2; Napo Pharmaceuticals2; Pfizer2; Prometheus Laboratories1; Roche1,2; Salix Pharmaceuticals, Inc.2; Samsung Bioepis2; Sandoz Pharmaceuticals2; Shire1,2; Takeda1,2; Target PharmaSolutions, Inc.2; UCB Pharma1
William J. Sandborn, MD, FACG AbbVie1,2; Allergan2; Amgen1,2; Atlantic Healthcare Limited1; Boehringer Ingelheim2; Celgene1,2; Conatus2; Cosmo2; Escalier Biosciences2,4; Ferring2; Genentech1,2; Gilead Sciences1,2; Gossamer Bio2,4; Janssen1,2; Lilly1,2; Miraca Life Sciences2; Nivalis Therapeutics2; Novartis Nutrition Science Partners2; Opplilan Pharma2,4; Otsuka2; Paul Hastings2; Pfizer2; Precision IBD2,4; Progenity2,4; Prometheus Laboratories2; Ritter Pharmaceuticals2,4; Robarts Clinical Trials2; Salix2; Seres Therapeutics2; Shire2; Sigmoid Biotechnologies2; Takeda2; Tigenix2; Tillotts Pharma2; UCB Pharma2; Vivelix2
Bruce E. Sands, MD, MS, FACG AbbVie2; Allergan Sales2; Amgen2; Arena Pharmaceuticals2; Boehringer Ingelheim2; Capella Biosciences2; Celgene2; EnGene2; Ferring2; Gilead2; Janssen2; Lilly2; Lyndra2; MedImmune2; Oppilan Pharma2; Otsuka2; Palatin Technologies2; Pfizer2; Progenity2; Rheos Pharmaceuticals2; Seres Therapeutics2; Synergy Pharmaceuticals2; Takeda2,3; Target Pharmasolutions2; Theravance Biopharma R&D, Inc.2; TiGenix2; Vivelix Pharmaceuticals2; WebMD3
David A. Schwartz, MD, FACG AbbVie2; Genentech2; Gilead2; Janssen2; Pfizer2; Takeda2; TiGenix2; UCB1,2
Bo Shen, MD AbbVie2,3; Janssen2; Takeda2,3
Corey A. Siegel, MD, MS AbbVie1,2,3; Amgen2; AGRQ (1R01HS021747-01) Broad Medical Research Program1; Celgene2,3; Colonary Concepts, LLC4,5; Crohn’s and Colitis Foundation1; Janssen1,2,3; Lilly2; MiTest Health, LLC4,5; Pfizer1,2,3; Prometheus2; Sandoz2; Sebela2; Takeda1,2,3; Spouse, Colonary Concepts, LLC4,5; MiTest Health, LLC4,5
Scott Strong, MD Ethicon2; Intuitive Surgical5
Eva M. Szigethy, MD, PhD, FACG APPI5; NIH1; Sherman Prize1; PCORI1
Thomas A. Ullman, MD, FACG Pfizer2
Douglas C. Wolf, MD, FACG AbbVie2,3; Arena2; Daiichi Sankyo3; Janssen2,3

The following speakers do not report any affiliation:

Maria T. Abreu, MD
Monica I. Ardura, DO
Jean H. Ashburn, MD
Eugene B. Chang, MD
Amy M. Donegan, APRN
Alessandro Fichera, MD
Phillip Fleshner, MD
Sonia Friedman, MD
Rachel Hendee, PA-C, MPH
Stefan Holubar, MD
Neil H. Hyman, MD
Maureen Kelly, DNP
Sergey Khaitov, MD
Sandra C. Kim, MD
Donald Kirby, MD
L. Campbell Levy, MD
Nicole Lopez, MD
Richard P. MacDermott, MD, MACG
Kristen Madden, APRN-PNP
Feza Remzi, MD
Michele Rubin, APN, MSN, CNS, CGRN
Daniela Simian, RN
Lauren K. Tormey, MD
Daniel von Allmen, MD
Karen Zaghiyan, MD, FACS
 

All materials are included with the permission of the authors.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Monalisa Singh and Susan Yarbrough disclosed no relevant financial relationships with any commercial interests.

NACCME and Imedex require faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Disclosure of off-label/unapproved uses of drugs and/or devices will be provided prior to the conference.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.